DK1622648T3 - DNA-vacciner mod tumorvækst og fremgangsmåder til anvendelse deraf - Google Patents

DNA-vacciner mod tumorvækst og fremgangsmåder til anvendelse deraf

Info

Publication number
DK1622648T3
DK1622648T3 DK04749425.7T DK04749425T DK1622648T3 DK 1622648 T3 DK1622648 T3 DK 1622648T3 DK 04749425 T DK04749425 T DK 04749425T DK 1622648 T3 DK1622648 T3 DK 1622648T3
Authority
DK
Denmark
Prior art keywords
human
protein
tumor growth
cancer
apoptosis
Prior art date
Application number
DK04749425.7T
Other languages
English (en)
Inventor
Rong Xiang
He Zhou
Ralph A Reisfeld
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK1622648T3 publication Critical patent/DK1622648T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
DK04749425.7T 2003-03-24 2004-03-24 DNA-vacciner mod tumorvækst og fremgangsmåder til anvendelse deraf DK1622648T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45700903P 2003-03-24 2003-03-24
PCT/US2004/008932 WO2004099389A2 (en) 2003-03-24 2004-03-24 Dna vaccines against tumor growth and methods of use thereof

Publications (1)

Publication Number Publication Date
DK1622648T3 true DK1622648T3 (da) 2010-09-06

Family

ID=33434911

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04749425.7T DK1622648T3 (da) 2003-03-24 2004-03-24 DNA-vacciner mod tumorvækst og fremgangsmåder til anvendelse deraf

Country Status (18)

Country Link
US (2) US8716254B2 (da)
EP (1) EP1622648B1 (da)
JP (1) JP4616827B2 (da)
KR (1) KR101199789B1 (da)
CN (1) CN1791433B (da)
AT (1) ATE472339T1 (da)
AU (1) AU2004236636B2 (da)
BR (1) BRPI0408774A (da)
CA (1) CA2519953C (da)
DE (1) DE602004027902D1 (da)
DK (1) DK1622648T3 (da)
ES (1) ES2345200T3 (da)
MX (1) MXPA05010255A (da)
PL (1) PL1622648T3 (da)
PT (1) PT1622648E (da)
RU (1) RU2343195C2 (da)
WO (1) WO2004099389A2 (da)
ZA (1) ZA200508579B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005294805B2 (en) 2004-05-28 2012-02-16 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
KR100790377B1 (ko) * 2006-02-15 2008-01-02 고려대학교 산학협력단 인터페론감마를 발현하는 살모넬라 균주를 함유하는항바이러스용 조성물
PL2035581T3 (pl) * 2006-06-21 2013-01-31 Scripps Research Inst Kompozycja DNA przeciwko FAP - antygenowi zrębowemu nowotworu i sposoby jej stosowania
CA2656700A1 (en) * 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
WO2008067305A2 (en) * 2006-11-28 2008-06-05 Giic Research Development Corporation Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CN101981187A (zh) 2008-03-31 2011-02-23 株式会社生物免疫平衡 MHC Ⅱ类分子提呈的存活蛋白(Survivin)的部分肽及其利用方法
EP2411503B1 (en) * 2009-03-27 2017-09-13 Eidgenössische Technische Hochschule Zürich Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof
RU2431669C2 (ru) * 2009-06-23 2011-10-20 Государственное образовательное учреждение высшего профессионального образования "Казанский государственный университет им. В.И. Ульянова-Ленина" Способ получения лекарственного препарата генетически модифицированных клеток
CA2769409A1 (en) * 2009-08-17 2011-02-24 The Penn State Research Foundation Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
KR101815322B1 (ko) * 2010-01-12 2018-01-05 서울대학교산학협력단 항암 펩타이드 서열
CN102985109B (zh) * 2010-06-25 2016-05-11 瓦西博迪公司 同型二聚体蛋白质构建体
CN102210862B (zh) * 2011-06-01 2013-06-12 中国人民解放军南京军区福州总医院 基于Livin的免疫刺激复合物及其制备方法和应用
PT2961831T (pt) * 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
AU2014228405B2 (en) * 2013-03-15 2017-05-11 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
US20160058856A1 (en) * 2013-04-05 2016-03-03 Kyushu University, National University Corporation Anti-tumor dna vaccine
US20160176943A1 (en) * 2013-07-05 2016-06-23 Inserm (Insititut National De La Sante Et De La Recherche Medicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
WO2015139020A2 (en) * 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
AU2015308695B2 (en) * 2014-08-29 2020-11-05 The Regents Of The University Of California Vaccine for livestock production systems
WO2016179573A1 (en) 2015-05-07 2016-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Variant survivin vaccine for treatment of cancer
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20180053318A (ko) 2015-09-17 2018-05-21 제이알엑스 바이오테크놀로지, 인코포레이티드 피부 수화 또는 보습을 향상시키기 위한 접근법
PL3356413T3 (pl) 2015-10-01 2022-04-19 Potenza Therapeutics, Inc. Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania
WO2018147801A1 (en) * 2017-02-07 2018-08-16 Agency For Science, Technology And Research Methods and kits for generating mimetic innate immune cells from pluripotent stem cells
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CN110448689A (zh) * 2019-08-06 2019-11-15 太仓美诺恒康生物技术有限公司 mRNA疫苗及其试剂盒、应用
US20230143947A1 (en) * 2019-09-20 2023-05-11 Crage Medical Co., Limited Immune effector cell in which expression is regulated by cytokines
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
RU2770490C1 (ru) * 2021-07-14 2022-04-18 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" Рекомбинантная плазмидная ДНК pET19b-Surv-OL, обеспечивающая синтез гибридного белка сурвивин-обелин (Surv-OL) и гибридный белок, связываемый анти-сурвивин антителами и обладающий биолюминесцентной активностью
CN116077534B (zh) * 2023-01-31 2024-08-27 大连工业大学 一种凝结芽孢杆菌的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) * 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
GB9104596D0 (en) * 1991-03-05 1991-04-17 Wellcome Found Production of recombinant proteins
US5702917A (en) * 1992-01-27 1997-12-30 Icos Corporation Polynucleotides encoding human ICAM-4
RU2077340C1 (ru) * 1993-08-06 1997-04-20 Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии Способ получения специфической сыворотки для лечения, диагностики и профилактики вирусной геморрагической болезни кроликов и набор для диагностики болезни
US5733760A (en) * 1994-08-05 1998-03-31 Virus Research Institute Salmonella vectors encoding truncated pag fusion protein, method of making, and uses thereof
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
RU2219942C2 (ru) * 1996-02-24 2003-12-27 Берингер Ингельхайм Интернациональ Гмбх Лекарственный состав с иммуномодуляторным действием, содержащий пептиды и вспомогательные средства
US6245523B1 (en) * 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
EP1015035B1 (en) * 1997-08-13 2009-01-28 The Uab Research Foundation Vaccination by topical application of genetic vectors
AU742757C (en) * 1997-12-17 2007-05-17 Immunex Corporation Cell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides
US20030215803A1 (en) * 2000-12-07 2003-11-20 Garcia Pablo Dominguez Human genes and gene expression products isolated from human prostate
WO2000003693A1 (en) * 1998-07-14 2000-01-27 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
IT1303683B1 (it) * 1998-10-30 2001-02-23 Menarini Ricerche Spa Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica.
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
AU765160B2 (en) * 1998-12-18 2003-09-11 Symrise Gmbh & Co. Kg Encapsulated flavour and/or fragrance preparations
AU2001273102A1 (en) * 2000-06-29 2002-01-14 The Salk Institute For Biological Studies Crystal structure of survivin
EP1256354A1 (en) * 2001-05-11 2002-11-13 Schering Corporation Methods for treating cancer
AU2002326961A1 (en) * 2001-10-10 2003-04-22 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
AU2003279770A1 (en) * 2002-10-01 2004-04-23 Novartis Vaccines And Diagnostics, Inc. Anti-cancer and anti-infectious disease compositions and methods for using same
WO2004055050A2 (en) * 2002-12-10 2004-07-01 Endocube Sas Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation

Also Published As

Publication number Publication date
JP2006523217A (ja) 2006-10-12
CA2519953A1 (en) 2004-11-18
DE602004027902D1 (de) 2010-08-12
EP1622648B1 (en) 2010-06-30
EP1622648A2 (en) 2006-02-08
US9655815B2 (en) 2017-05-23
EP1622648A4 (en) 2007-02-14
CN1791433B (zh) 2010-05-26
WO2004099389A2 (en) 2004-11-18
CN1791433A (zh) 2006-06-21
US20040192631A1 (en) 2004-09-30
WO2004099389A3 (en) 2005-09-29
ES2345200T3 (es) 2010-09-17
PT1622648E (pt) 2010-08-31
RU2005132578A (ru) 2006-05-10
BRPI0408774A (pt) 2006-03-28
ATE472339T1 (de) 2010-07-15
CA2519953C (en) 2016-01-05
KR101199789B1 (ko) 2012-11-09
US20140322249A1 (en) 2014-10-30
AU2004236636A1 (en) 2004-11-18
RU2343195C2 (ru) 2009-01-10
JP4616827B2 (ja) 2011-01-19
AU2004236636B2 (en) 2010-02-04
KR20050121694A (ko) 2005-12-27
US8716254B2 (en) 2014-05-06
MXPA05010255A (es) 2005-12-14
PL1622648T3 (pl) 2010-11-30
ZA200508579B (en) 2007-04-25

Similar Documents

Publication Publication Date Title
DK1622648T3 (da) DNA-vacciner mod tumorvækst og fremgangsmåder til anvendelse deraf
Hollingsworth et al. Turning the corner on therapeutic cancer vaccines
Li et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself
Moschella et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
Cicchelero et al. Various ways to improve whole cancer cell vaccines
WO1998016238A3 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
ATE272407T1 (de) Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff
Morris et al. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer
Ren et al. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles)
Pilon-Thomas et al. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model
CN115702927A (zh) 一种广谱性肿瘤疫苗增效的组合物
Ding et al. Coadministration of the fungal immunomodulatory protein FIP‐Fve and a tumour‐associated antigen enhanced antitumour immunity
WO2004027036A3 (en) Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
ATE547529T1 (de) Materialien und verfahren im zusammenhang mit verbesserten impfstrategien
Macedo et al. Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles
Tewari et al. Dendritic cell therapy in advanced gastric cancer: a promising new hope?
Krejci et al. Immunotherapy for urological malignancies
Grippin et al. Abstract B125: SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade
Garcia Paz et al. The relationship between the antitumor effect of the IL‐12 gene therapy and the expression of Th1 cytokines in an HPV16‐positive murine tumor model
Shafer-Weaver et al. T cell tolerance to tumors and cancer immunotherapy
Naylor et al. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines
Schirrmacher T cell-mediated immunotherapy of metastases: state of the art in 2005
Schabowsky et al. ProtEx™ technology for the generation of novel therapeutic cancer vaccines
Yang et al. Dendritic cells pulsed with GST–EGFR fusion protein: Effect in antitumor immunity against head and neck squamous cell carcinoma
Kabaker et al. Vaccines for colorectal cancer and renal cell carcinoma